Imagen de Portada

Clinical Development and Perspectives of CIMAvax EGF, Cuban Vaccine for Non-small-cell Lung Cancer Therapy

Fuente: Redalyc

Guardado en:

Detalles Bibliográficos
Autor principal:	Pedro C Rodríguez
Formato:	Artículo científico
Lenguaje:	en
Publicado:	Medical Education Cooperation with Cuba 2010
Materias:	Medicina non small lung cancer EGF receptor immunotherapy
Acceso en línea:	Acceder al recurso
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Clinical Experience with Nimotuzumab in Cuban Pediatric Patients with Brain Tumors, 2005 to 2007
por: Giselle Saurez
Publicado: (2009)

Length of Diagnostic Delay in Patients with Non-small-cell Lung Cancer
por: Solangel Valdés
Publicado: (2010)

Supervivencia libre de progresión de cáncer pulmonar de células no pequeñas en pacientes vacunados con CIMAvax-EGF
por: Francisco Martínez Feria
Publicado: (2015)

Supervivencia en pacientes con cáncer pulmonar de células no pequeñas vacunados con CIMAvax-EGF
por: Carlos Oliver Cobián Caballero
Publicado: (2016)

Is diabetes mellitus a negative prognostic factor for the treatment of advanced non-small-cell lung cancer?
por: Ali Inal
Publicado: (2014)

Journal for ImmunoTherapy of Cancer
Publicado: (2013)

Del nuevo producto biológico para el cáncer al impacto en la salud poblacional
por: Agustín Lage Dávila
Publicado: (2012)

Uso de la vacuna CIMAvax-EGF® como práctica médica habitual
por: Justa Carmen Columbié Regüeiferos
Publicado: (2019)

Racotumomab in Non-Small Cell Lung Cancer as Maintenance and Second-Line Treatment
por: Haslen H. Cáceres-Lavernia
Publicado: (2021)

Cancer survival in Cali, Colombia: A population-based study, 1995-2004
por: Luís Eduardo Bravo
Publicado: (2014)

Lung Cancer: Targets and Therapy
Publicado: (2010)

Malignant pulmonary neoplasms predisposing to pneumothorax
por: Saulius Cicėnas
Publicado: (2011)

Surgery for lung cancer as the second primary malignancy
por: Arnoldas Krasauskas
Publicado: (2012)

Journal of Current Oncology and Medical Sciences
Publicado: (2023)

Molecular Therapy: Oncology
Publicado: (2024)

Journal of the National Cancer Center
Publicado: (2021)

Heberprot-P: A Novel Product for Treating Advanced Diabetic Foot Ulcer
por: Jorge Berlanga
Publicado: (2013)

LOSTdb datasets - Part 2
por: L, H
Publicado: (2025)

MedComm – Oncology
Publicado: (2023)

JTO Clinical and Research Reports
Publicado: (2021)

Heberprot-P’s Effect on Gene Expression in Healing Diabetic Foot Ulcers
por: Hanlet Camacho-Rodríguez
Publicado: (2018)

ESMO Gastrointestinal Oncology
Publicado: (2024)

Hormone Receptors and Other Prognostic Factors in Breast Cancer in Cuba
por: Rosa Irene Álvarez Goyanes
Publicado: (2010)

Methods of main bronchus stump closure and incidence of bronchopleural fistula after pneumonectomies for lung cancer (a retrospective single center review)
por: Saulius Cicėnas
Publicado: (2013)

Aplicación de productos inmunoterapéuticos en ensayos clínicos oncológicos en Santiago de Cuba
por: Oneyda Clapé Laffita
Publicado: (2017)

Evolving T-Cells to Outsmart Cancer
por: Eka, Ememobong
Publicado: (2025)

Role of active and passive smoking on lung cancer etiology in Mexico City
por: Alexander Corcho Berdugo
Publicado: (2006)

Advances in antibody-based strategies for targeting cancer-associated glycopeptide antigens
por: Meier, Edward, et al.
Publicado: (2025)

Immuno-Oncology and Technology
Publicado: (2021)

Figure 3 from: Arabadjiev J, Krasteva R, Robev B, Tonev I, Tzonev N, Todorova T, Bivolarski I, Milushewa P, Tzanev T, Dekov D, Mitov K, Dimitrova M (2026) The journey of lung cancer patients through the health care system in Bulgaria: Insights from patient-reported outcomes. Pharmacia 73: 1-7. https://doi.org/10.3897/pharmacia.73.e192001
por: Arabadjiev, Jeliazko, et al.
Publicado: (2026)

Южно-Российский онкологический журнал
Publicado: (2022)

Figure 1 from: Ivanov H, Stoyanova V, Linev A, Pochileev I, Chirlova-Kulenska A, Chapkanov A, Dimov R (2026) Postoperative circulating cell-free DNA (cfDNA) dynamics as an early indicator of molecular residual disease in lung cancer: preliminary results and correlation with TNM status, adjuvant therapy, and clinical outcome. Pharmacia 73: e187008. https://doi.org/10.3897/pharmacia.73.e187008
por: Ivanov, Hristo, et al.
Publicado: (2026)

Modifying γδ T cells for cancer treatment: a systematic review
por: Ma, Ling
Publicado: (2026)

Therapeutic Advances in Vaccines and Immunotherapy
Publicado: (2019)

Social welfare of workers affected by a chronic lung disease
por: Adela Reig-Botella
Publicado: (2018)

Nanoparticle-based therapy for respiratory diseases
por: ADRIANA L. DA SILVA
Publicado: (2013)

Effects of non-invasive ventilation and posture on chest wall volumes and motion in patients with amyotrophic lateral sclerosis: a case series
por: Cristiana M. Magalhães
Publicado: (2016)

Tuberculosis and Respiratory Diseases
Publicado: (2018)

Transbronchial lung cryobiopsy: Associated complications
por: R. Linhas
Publicado: (2017)

Zhongliu Fangzhi Yanjiu
Publicado: (2019)